The dietary phase 2 protein inducer sulforaphane can normalize the kidney epigenome and improve blood pressure in hypertensive rats

American Journal of Hypertension

Volumn 25, Issue 2, 2012, Pages 229-235

  Senanayake, Gamarallage V K ^a,b   Banigesh, Ali ^a   Wu, Lingyun ^a   Lee, Paul ^a   Juurlink, Bernhard H J ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

anti oxidant defenses; blood pressure; global DNA methylation; hypertension; renal pathology; spontaneously hypertensive stroke prone rats; Sprague Dawley; sulforaphane; vascular changes

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYTOSINE DERIVATIVE; DEOXYCYTOSINE; DNA; SULFORAPHANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CELL COUNT; CONTROLLED STUDY; DNA METHYLATION; FEEDING; FEMALE; FUNCTIONAL MORPHOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HYPERTENSION; KIDNEY ARTERY; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NITRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HYPERTENSION; KIDNEY; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; THIOCYANATES;

EID: 84856059079     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.200     Document Type: Article

References (40)

1. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104:545-556. (Pubitemid 32201949)
2. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000; 101:329-335. (Pubitemid 30054162)
3. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension 2004; 43: 1239-1245. (Pubitemid 38691746)
4. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest 2004; 114:1146-1157. (Pubitemid 39578704)
5. Aviv A, Aviv H. Telomeres and essential hypertension. Am J Hypertens 1999; 12:427-432. (Pubitemid 29200063)
6. Holliday R. The inheritance of epigenetic defects. Science 1987; 238:163-170. (Pubitemid 17139717)
7. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008; 31(Suppl 2):S181-S184.
8. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15:1983-1992. (Pubitemid 39031337)
9. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44:248-252. (Pubitemid 39167216)
10. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 2004; 32: 4100-4108. (Pubitemid 39232282)
11. Noyan-Ashraf MH, Wu L, Wang R, Juurlink BH. Dietary approaches to positively influence fetal determinants of adult health. FASEB J 2006; 20:371-373. (Pubitemid 46671175)
12. Ojeda NB, Grigore D, Alexander BT. Intrauterine growth restriction: fetal programming of hypertension and kidney disease. Adv Chronic Kidney Dis 2008; 15:101-106. (Pubitemid 351335411)
13. Fornage M. Unraveling hypertension: epigenomics comes of age. Pharmacogenomics 2007; 8:125-128.
14. Nabika T, Cui Z, Masuda J. The stroke-prone spontaneously hypertensive rat: how good is it as a model for cerebrovascular diseases? Cell Mol Neurobiol 2004; 24:639-646. (Pubitemid 39062427)
15. Tawa R, Ono T, Kurishita A, Okada S, Hirose S. Changes of DNA methylation level during pre-and postnatal periods in mice. Differentiation 1990; 45:44-48. (Pubitemid 20346653)
16. Juurlink BH. Therapeutic potential of dietary phase 2 enzyme inducers in ameliorating diseases that have an underlying inflammatory component. Can J Physiol Pharmacol 2001; 79:266-282. (Pubitemid 32289666)
17. Rettig R, Folberth C, Kopf D, Stauss H, Unger T. Role of the kidney in the pathogenesis of primary hypertension. Clin Exp Hypertens A 1990; 12:957-1002. (Pubitemid 20281368)
18. Biswas SK, de Faria JB. Which comes first: renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res 2007; 41:216-224. (Pubitemid 46992872)
19. Nørrelund H, Christensen KL, Samani NJ, Kimber P, Mulvany MJ, Korsgaard N. Early narrowed afferent arteriole is a contributor to the development of hypertension. Hypertension 1994; 24:301-308. (Pubitemid 24278059)
20. Feld LG, Van Liew JB, Galaske RG, Boylan JW. Selectivity of renal injury and proteinuria in the spontaneously hypertensive rat. Kidney Int 1977; 12:332-343. (Pubitemid 8249780)
21. Zhou XJ, Vaziri ND, Zhang J, Wang HW, Wang XQ. Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade. Kidney Int 2002; 62:914-921. (Pubitemid 35316720)
22. Smeda JS, Lee RM, Forrest JB. Structural and reactivity alterations of the renal vasculature of spontaneously hypertensive rats prior to and during established hypertension. Circ Res 1988; 63:518-533.
23. Skov K, Mulvany MJ. Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Physiol Scand 2004; 181:397-405. (Pubitemid 39078835)
24. Smeda JS, Lee RM, Forrest JB. Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988; 63:534-542.
25. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39:135-141. (Pubitemid 34100448)
26. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, Mohan A, Pan S, Li L, Jin ZG, Yan C, Abe J, Berk BC. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008; 117:3088-3098.
27. Lee DH, O'Connor TR, Pfeifer GP. Oxidative DNA damage induced by copper and hydrogen peroxide promotes CG-TT tandem mutations at methylated CpG dinucleotides in nucleotide excision repair-deficient cells. Nucleic Acids Res 2002; 30:3566-3573. (Pubitemid 34919212)
28. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61:3573-3577. (Pubitemid 32694963)
29. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407-414. (Pubitemid 24346056)
30. Zhao Q, Wang L, Yang W, Chen S, Huang J, Fan Z, Li H, Lu X, Gu D. Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. Pharmacogenet Genomics 2008; 18:459-466. (Pubitemid 351769914)
31. Nuyt AM. Mechanisms underlying developmental programming of elevated blood pressure and vascular dysfunction: evidence from human studies and experimental animal models. Clin Sci (Lond) 2008; 114:1-17.
32. Wyrwoll CS, Mark PJ, Waddell BJ. Developmental programming of renal glucocorticoid sensitivity and the renin-angiotensin system. Hypertension 2007; 50:579-584. (Pubitemid 47312247)
33. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-298. (Pubitemid 46439286)
34. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat Rev Genet 2004; 5:446-455. (Pubitemid 38915411)
35. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006; 9:199-207. (Pubitemid 43357946)
36. Lund G, Andersson L, Lauria M, Lindholm M, Fraga MF, Villar-Garea A, Ballestar E, Esteller M, Zaina S. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004; 279:29147-29154. (Pubitemid 38915787)
37. Yehezkel S, Segev Y, Viegas-Péquignot E, Skorecki K, Selig S. Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions. Hum Mol Genet 2008; 17:2776-2789.
38. Fuster JJ, Díez J, Andrés V. Telomere dysfunction in hypertension. J Hypertens 2007; 25:2185-2192. (Pubitemid 47537907)
39. Cao Y, Li H, Mu FT, Ebisui O, Funder JW, Liu JP. Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension. FASEB J 2002; 16:96-98.
40. Smolarek I, Wyszko E, Barciszewska AM, Nowak S, Gawronska I, Jablecka A, Barciszewska MZ. Global DNA methylation changes in blood of patients with essential hypertension. Med Sci Monit 2010; 16:CR149-CR155.